Binnopharm Group has Expanded Its Line of Women’s Health Products
Binnopharm Group, one of the leaders in the Russian pharmaceutical market, announces the expansion of its portfolio of women’s health products. Three new drugs, such as DESERIA®, which is a contraceptive, DIDROMENS®, which is intended for treatment of a wide range of conditions associated with progesterone deficiency, and GINOCARE®, an antiviral drug for external use, have become commercially available.
In addition, NORMETRILLA (dienogest), an endometriosis treatment drug which was brought to the market in June 2025, has gained a significant market share of 8.5% (in numbers of packages) in just a few months. To date, more than 11,200 packages have been sold, and the distribution rate has reached 12% (more than 12,000 pharmacies).
Ekaterina Slavgorodskaya, Sales and Promotion Director at Binnopharm Group: «By developing our portfolio of women’s health products, we strive for one main goal: to ensure the well-being of every woman. To achieve this, we not only strengthen our product line with modern drugs, but also guarantee their availability through our own production expertise and optimised supply chains».
The expansion of the gynaecological product line demonstrates the consistent implementation of Binnopharm Group’s strategy aimed at providing Russian women with high-quality, effective and affordable medicines to maintain their health at all stages of life.
